De novo lipogenesis in the liver in health and disease: More than just a shunting yard for glucose

Biological Reviews

Volumn 91, Issue 2, 2016, Pages 452-468

  Sanders, Francis W B ^a,b   Griffin, Julian L ^a,b  

^a MRC HUMAN NUTRITION RESEARCH   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

de novo lipogenesis (DNL); Fructose; Liver; Non alcoholic fatty liver disease (NAFLD); Selective insulin resistance

Indexed keywords

GLUCOSE; GLUCOSE BLOOD LEVEL;

ANIMAL; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPOGENESIS; LIVER DISEASE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; LIPOGENESIS; LIVER DISEASES; PREDIABETIC STATE;

EID: 84923862739     PISSN: 14647931     EISSN: 1469185X     Source Type: Journal    
DOI: 10.1111/brv.12178     Document Type: Article

References (175)

1. Aarsland, A., Chinkes, D. & Wolfe, R. R. (1996). Contributions of de novo synthesis of fatty acids to total VLDL-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man. Journal of Clinical Investigation 98, 2008-2017.
2. Abu-Elheiga, L., Brinkley, W. R., Zhong, L., Chirala, S. S., Woldegiorgis, G. & Wakil, S. J. (2000). The subcellular localization of acetyl-CoA carboxylase 2. Proceedings of the National Academy of Sciences of the United States of America 97, 1444-1449.
3. Abu-Shanab, A. & Quigley, E. M. M. (2010). The role of the gut microbiota in nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology 7, 691-701.
4. Aguado, B. & Campbell, R. D. (1998). Characterization of a human lysophosphatidic acid acyltransferase that is encoded by a gene located in the class III region of the human major histocompatibility complex. Journal of Biological Chemistry 273, 4096-4105.
5. Ahmad, F., Ahmad, P. M., Pieretti, L. & Watters, G. T. (1978). Purification and subunit structure of rat mammary gland acetyl coenzyme A carboxylase. Journal of Biological Chemistry 253, 1733-1737.
6. Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M. & Smith, S. C. (2009). Harmonizing the metabolic syndrome A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640-1645.
7. Alexander, C. A., Hamilton, R. L. & Havel, R. J. (1976). Subcellular localization of B apoprotein of plasma lipoproteins in rat liver. The Journal of Cell Biology 69, 241-263.
8. Almeda-Valdés, P., Cuevas-Ramos, D. & Aguilar-Salinas, C. A. (2009). Metabolic syndrome and non-alcoholic fatty liver disease. Annals of Hepatology 8(Suppl. 1), S18-S24.
9. Ameer, F., Scandiuzzi, L., Hasnain, S., Kalbacher, H. & Zaidi, N. (2014). De novo lipogenesis in health and disease. Metabolism 63, 895-902.
10. Ament, Z., Masoodi, M. & Griffin, J. L. (2012). Applications of metabolomics for understanding the action of peroxisome proliferator-activated receptors (PPARs) in diabetes, obesity and cancer. Genome Medicine 4, 32.
11. Arden, C., Tudhope, S. J., Petrie, J. L., Al-Oanzi, Z. H., Cullen, K. S., Lange, A. J., Towle, H. C. & Agius, L. (2012). Fructose 2, 6-bisphosphate is essential for glucose-regulated gene transcription of glucose-6-phosphatase and other ChREBP target genes in hepatocytes. Biochemical Journal 443, 111-123.
12. Bae, J. C., Rhee, E. J., Lee, W. Y., Park, S. E., Park, C. Y., Oh, K. W., Park, S. W. & Kim, S. W. (2011). Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes. Diabetes Care 34, 727-729.
13. Basaranoglu, M. (2013). Fructose as a key player in the development of fatty liver disease. World Journal of Gastroenterology 19, 1166-1172.
14. Bass, N. M. (1990). Fatty acid-binding protein expression in the liver: its regulation and relationship to the zonation of fatty acid metabolism. Molecular and Cellular Biochemistry 98, 167-176.
15. Bergheim, I., Weber, S., Vos, M., Krämer, S., Volynets, V., Kaserouni, S., McClain, C. J. & Bischoff, S. C. (2008). Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. Journal of Hepatology 48, 983-992.
16. Bianchi, A., Evans, J. L., Iverson, A. J., Nordlund, A. C., Watts, T. D. & Witters, L. A. (1990). Identification of an isozymic form of acetyl-CoA carboxylase. Journal of Biological Chemistry 265, 1502-1509.
17. Boone, A. N., Chan, A., Kulpa, J. E. & Brownsey, R. W. (2000). Bimodal activation of acetyl-CoA carboxylase by glutamate. Journal of Biological Chemistry 275, 10819-10825.
18. Bray, G. A. & York, D. A. (1979). Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiological Reviews 59, 719-809.
19. Brindley, D. N., Matsumura, S. & Bloch, K. (1969). Mycobacterium phlei fatty acid synthetase-A bacterial multienzyme complex. Nature 224, 666-669.
20. Brown, M. S. & Goldstein, J. L. (2008). Selective versus total insulin resistance: a pathogenic paradox. Cell Metabolism 7, 95-96.
21. Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M. & Hobbs, H. H. (2004). Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387-1395.
22. Brownsey, R. W., Boone, A. N., Elliott, J. E., Kulpa, J. E. & Lee, W. M. (2006). Regulation of acetyl-CoA carboxylase. Biochemical Society Transactions 34, 223-227.
23. Cabezas, J., Mayorga, M. & Crespo, J. (2012). Nonalcoholic fatty liver disease: a pathological view. In Liver Biopsy - Indications, Procedures, Results (ed. N. Tagaya ), pp. 161-188. InTech, Croatia.
24. Carey, E. M., Dils, R. & Hansen, H. J. (1970). Short communications. Chain-length specificity for termination of atty acid biosynthesis by fatty acid synthetase complexes from lactating rabbit mamary gland and rat liver. Biochemical Journal 117, 633-635.
25. Chakravarty, B., Gu, Z., Chirala, S. S., Wakil, S. J. & Quiocho, F. A. (2004). Human fatty acid synthase: structure and substrate selectivity of the thioesterase domain. Proceedings of the National Academy of Sciences of the United States of America 101, 15567-15572.
26. Chalasani, N., Wilson, L., Kleiner, D. E., Cummings, O. W., Brunt, E. M. & Unalp, A. (2008). Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. Journal of Hepatology 48, 829-834.
27. Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M. & Sanyal, A. J. (2012). The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142, 1592-1609.
28. Chang, S. I. & Hammes, G. G. (1990). Structure and mechanism of action of a multifunctional enzyme: fatty acid synthase. Accounts of Chemical Research 23, 363-369.
29. Chavez, J. A., Knotts, T. A., Wang, L.-P., Li, G., Dobrowsky, R. T., Florant, G. L. & Summers, S. A. (2003). A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. Journal of Biological Chemistry 278, 10297-10303.
30. Chavez, J. A. & Summers, S. A. (2010). Lipid oversupply, selective insulin resistance, and lipotoxicity: Molecular mechanisms. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1801, 252-265.
31. Chawla, A., Repa, J. J., Evans, R. M. & Mangelsdorf, D. J. (2001). Nuclear receptors and lipid physiology: opening the X-Files. Science 294, 1866-1870.
32. Choi, S. H. & Ginsberg, H. N. (2011). Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends in Endocrinology & Metabolism 22, 353-363.
33. Coleman, R. A. & Lee, D. P. (2004). Enzymes of triacylglycerol synthesis and their regulation. Progress in Lipid Research 43, 134-176.
34. Debois, D., Bralet, M.-P., Le Naour, F., Brunelle, A. & Laprévote, O. (2009). In situ lipidomic analysis of nonalcoholic fatty liver by cluster TOF-SIMS imaging. Analytical Chemistry 81, 2823-2831.
35. Dekker, M. J., Su, Q., Baker, C., Rutledge, A. C. & Adeli, K. (2010). Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. American Journal of Physiology - Endocrinology and Metabolism 299, E685-E694.
36. Dentin, R., Tomas-Cobos, L., Foufelle, F., Leopold, J., Girard, J., Postic, C. & Ferré, P. (2012). Glucose 6-phosphate, rather than xylulose 5-phosphate, is required for the activation of ChREBP in response to glucose in the liver. Journal of Hepatology 56, 199-209.
37. Diraison, F., Moulin, P. & Beylot, M. (2003). Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes & Metabolism 29, 478-485.
38. Diraison, F., Pachiaudi, C. & Beylot, M. (1997). Measuring lipogenesis and cholesterol synthesis in humans with deuterated water: use of simple gas chromatographic/mass spectrometric techniques. Journal of Mass Spectrometry: JMS 32, 81-86.
39. Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D. & Parks, E. J. (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. Journal of Clinical Investigation 115, 1343-1351.
40. Douard, V. & Ferraris, R. P. (2008). Regulation of the fructose transporter GLUT5 in health and disease. American Journal of Physiology - Endocrinology and Metabolism 295, E227-E237.
41. Endo, H., Niioka, M., Kobayashi, N., Tanaka, M. & Watanabe, T. (2013). Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis. PLoS ONE 8, e63388.
42. Eslamparast, T., Eghtesad, S., Hekmatdoost, A. & Poustchi, H. (2013). Probiotics and nonalcoholic fatty liver disease. Middle East Journal of Digestive Diseases 5, 129-136.
43. Ferré, P. & Foufelle, F. (2010). Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes, Obesity and Metabolism 12, 83-92.
44. Fischer, H., Ellström, P., Ekström, K., Gustafsson, L., Gustafsson, M. & Svanborg, C. (2007). Ceramide as a TLR4 agonist; a putative signalling intermediate between sphingolipid receptors for microbial ligands and TLR4. Cellular Microbiology 9, 1239-1251.
45. Fon Tacer, K. & Rozman, D. (2011). Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation. Journal of Lipids 2011, 1-14.
46. Foster, D. W. & Bloom, B. (1963). The synthesis of fatty acids by rat liver slices in tritiated water. Journal of Biological Chemistry 238, 888-892.
47. Frevert, U., Engelmann, S., Zougbédé, S., Stange, J., Ng, B., Matuschewski, K., Liebes, L. & Yee, H. (2005). Intravital observation of plasmodium berghei sporozoite infection of the liver. PLoS Biology 3, e192.
48. Gaggini, M., Morelli, M., Buzzigoli, E., DeFronzo, R. A., Bugianesi, E. & Gastaldelli, A. (2013). Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 5, 1544-1560.
49. Galadari, S., Rahman, A., Pallichankandy, S., Galadari, A. & Thayyullathil, F. (2013). Role of ceramide in diabetes mellitus: evidence and mechanisms. Lipids in Health and Disease 12, 1-16.
50. Gan, X., Wang, J., Su, B. & Wu, D. (2011). Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3, 4, 5-trisphosphate. The Journal of Biological Chemistry 286, 10998-11002.
51. Garg, A. (2000). Lipodystrophies. The American Journal of Medicine 108, 143-152.
52. Gaussin, V., Hue, L., Stalmans, W. & Bollen, M. (1996). Activation of hepatic acetyl-CoA carboxylase by glutamate and Mg2+ is mediated by protein phosphatase-2A. Biochemical Journal 316, 217-224.
53. Grefhorst, A., Elzinga, B. M., Voshol, P. J., Plösch, T., Kok, T., Bloks, V. W., van der Sluijs, F. H., Havekes, L. M., Romijn, J. A., Verkade, H. J. & Kuipers, F. (2002). Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. Journal of Biological Chemistry 277, 34182-34190.
54. Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., Spertus, J. A. & Costa, F. (2005). Diagnosis and management of the metabolic syndrome an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735-2752.
55. Guo, S. (2014). Insulin signaling, resistance, and metabolic syndrome: insights from mouse models into disease mechanisms. Journal of Endocrinology 220, T1-T23.
56. Ha, J., Daniel, S., Broyles, S. S. & Kim, K. H. (1994). Critical phosphorylation sites for acetyl-CoA carboxylase activity. Journal of Biological Chemistry 269, 22162-22168.
57. Hagiwara, A., Cornu, M., Cybulski, N., Polak, P., Betz, C., Trapani, F., Terracciano, L., Heim, M. H., Rüegg, M. A. & Hall, M. N. (2012). Hepatic mTORC2 activates glycolysis and lipogenesis through akt, glucokinase, and SREBP1c. Cell Metabolism 15, 725-738.
58. Hajduch, E., Turban, S., Le Liepvre, X., Le Lay, S., Lipina, C., Dimopoulos, N., Dugail, I. & Hundal, H. S. (2008). Targeting of PKCζ and PKB to caveolin-enriched microdomains represents a crucial step underpinning the disruption in PKB-directed signalling by ceramide. Biochemical Journal 410, 369-379.
59. Hamaguchi, M., Kojima, T., Takeda, N., Nagata, C., Takeda, J., Sarui, H., Kawahito, Y., Yoshida, N., Suetsugu, A., Kato, T., Okuda, J., Ida, K. & Yoshikawa, T. (2007). Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World Journal of Gastroenterology: WJG 13, 1579-1584.
60. Hamaguchi, M., Kojima, T., Takeda, N., Nakagawa, T., Taniguchi, H., Fujii, K., Omatsu, T., Nakajima, T., Sarui, H., Shimazaki, M., Kato, T., Okuda, J. & Ida, K. (2005). The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Annals of Internal Medicine 143, 722-728.
61. Hegarty, B. D., Bobard, A., Hainault, I., Ferré, P., Bossard, P. & Foufelle, F. (2005). Distinct roles of insulin and liver X receptor in the induction and cleavage of sterol regulatory element-binding protein-1c. Proceedings of the National Academy of Sciences of the United States of America 102, 791-796.
62. Hellerstein, M. K., Christiansen, M., Kaempfer, S., Kletke, C., Wu, K., Reid, J. S., Mulligan, K., Hellerstein, N. S. & Shackleton, C. H. (1991). Measurement of de novo hepatic lipogenesis in humans using stable isotopes. Journal of Clinical Investigation 87, 1841-1852.
63. Hers, H. G. (1952). La fructokinase du foie. Biochimica et Biophysica Acta 8, 416-423.
64. Higuchi, N., Kato, M., Shundo, Y., Tajiri, H., Tanaka, M., Yamashita, N., Kohjima, M., Kotoh, K., Nakamuta, M., Takayanagi, R. & Enjoji, M. (2008). Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatology Research 38, 1122-1129.
65. Hijmans, B. S., Grefhorst, A., Oosterveer, M. H. & Groen, A. K. (2013). Zonation of glucose and fatty acid metabolism in the liver: mechanism and metabolic consequences. Biochimie 96, 121-129.
66. Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M. & Hotamisligil, G. S. (2002). A central role for JNK in obesity and insulin resistance. Nature 420, 333-336.
67. Holland, W. L., Brozinick, J. T., Wang, L.-P., Hawkins, E. D., Sargent, K. M., Liu, Y., Narra, K., Hoehn, K. L., Knotts, T. A., Siesky, A., Nelson, D. H., Karathanasis, S. K., Fontenot, G. K., Birnbaum, M. J. & Summers, S. A. (2007). Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metabolism 5, 167-179.
68. Hwahng, S. H., Ki, S. H., Bae, E. J., Kim, H. E. & Kim, S. G. (2009). Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology 49, 1913-1925.
69. Iizuka, K., Bruick, R. K., Liang, G., Horton, J. D. & Uyeda, K. (2004). Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proceedings of the National Academy of Sciences of the United States of America 101, 7281-7286.
70. Ishibashi, H., Nakamura, M., Komori, A., Migita, K. & Shimoda, S. (2009). Liver architecture, cell function, and disease. Seminars in Immunopathology 31, 399-409.
71. Jensen-Urstad, A. P. L. & Semenkovich, C. F. (2012). Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger? Biochimica et Biophysica Acta 1821, 747-753.
72. Jimba, S., Nakagami, T., Takahashi, M., Wakamatsu, T., Hirota, Y., Iwamoto, Y. & Wasada, T. (2005). Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabetic Medicine 22, 1141-1145.
73. Jitrapakdee, S. (2012). Transcription factors and coactivators controlling nutrient and hormonal regulation of hepatic gluconeogenesis. The International Journal of Biochemistry & Cell Biology 44, 33-45.
74. Jungermann, K. & Keitzmann, T. (1996). Zonation of parenchymal and nonparenchymal metabolism in liver. Annual Review of Nutrition 16, 179-203.
75. Karim, S. (2012). Hepatic expression and cellular distribution of the glucose transporter family. World Journal of Gastroenterology 18(46): 6771-6781.
76. Katz, N. R. (1992). Metabolic heterogeneity of hepatocytes across the liver acinus. The Journal of Nutrition 122, 843-849.
77. Kawano, Y. & Cohen, D. (2013). Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. Journal of Gastroenterology 48, 434-441.
78. Kelpe, C. L., Moore, P. C., Parazzoli, S. D., Wicksteed, B., Rhodes, C. J. & Poitout, V. (2003). Palmitate inhibition of insulin gene expression is mediated at the transcriptional level via ceramide synthesis. Journal of Biological Chemistry 278, 30015-30021.
79. Kim, C.-W., Moon, Y.-A., Park, S. W., Cheng, D., Kwon, H. J. & Horton, J. D. (2010). Induced polymerization of mammalian acetyl-CoA carboxylase by MIG12 provides a tertiary level of regulation of fatty acid synthesis. Proceedings of the National Academy of Sciences of the United States of America 107, 9626-9631.
80. Knebel, B., Haas, J., Hartwig, S., Jacob, S., Kollmer, C., Nitzgen, U., Muller-Wieland, D. & Kotzka, J. (2012). Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass. PLoS ONE 7, e31812.
81. Kohjima, M., Higuchi, N., Kato, M., Kotoh, K., Yoshimoto, T., Fujino, T., Yada, M., Yada, R., Harada, N., Enjoji, M., Takayanagi, R. & Nakamuta, M. (2008). SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. International Journal of Molecular Medicine 21, 507-511.
82. Korenblat, K. M., Fabbrini, E., Mohammed, B. S. & Klein, S. (2008). Liver, muscle and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 134, 1369-1375.
83. Kotronen, A., Juurinen, L., Hakkarainen, A., Westerbacka, J., Cornér, A., Bergholm, R. & Yki-Järvinen, H. (2008). Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 31, 165-169.
84. Kotronen, A., Seppanen-Laakso, T., Westerbacka, J., Kiviluoto, T., Arola, J., Ruskeepaa, A.-L., Oresic, M. & Yki-Jarvinen, H. (2009a). Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 58, 203-208.
85. Kotronen, A., Velagapudi, V. R., Yetukuri, L., Westerbacka, J., Bergholm, R., Ekroos, K., Makkonen, J., Taskinen, M. R., Orešič, M. & Yki-Järvinen, H. (2009b). Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia 52, 684-690.
86. Laville, M. & Nazare, J. A. (2009). Diabetes, insulin resistance and sugars. Obesity Reviews 10, 24-33.
87. Leavens, K. F., Easton, R. M., Shulman, G. I., Previs, S. F. & Birnbaum, M. J. (2009). Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metabolism 10, 405-418.
88. Lee, J. Y., Kim, K. M., Lee, S. G., Yu, E., Lim, Y.-S., Lee, H. C., Chung, Y.-H., Lee, Y. S. & Suh, D.-J. (2007). Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. Journal of Hepatology 47, 239-244.
89. Lewis, G. F., Carpentier, A., Adeli, K. & Giacca, A. (2002). Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine Reviews 23, 201-229.
90. Li, S., Brown, M. S. & Goldstein, J. L. (2010). Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proceedings of the National Academy of Sciences of the United States of America 107, 3441-3446.
91. Lim, J. S., Mietus-Snyder, M., Valente, A., Schwarz, J.-M. & Lustig, R. H. (2010). The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nature Reviews Gastroenterology and Hepatology 7, 251-264.
92. Lin, C. Y. & Smith, S. (1978). Properties of the thioesterase component obtained by limited trypsinization of the fatty acid synthetase multienzyme complex. Journal of Biological Chemistry 253, 1954-1962.
93. Ludwig, J., Viggiano, T. R., McGill, D. B. & Oh, B. J. (1980). Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings 55, 434-438.
94. Ma, L., Tsatsos, N. G. & Towle, H. C. (2005). Direct role of ChREBP · Mlx in regulating hepatic glucose-responsive genes. Journal of Biological Chemistry 280, 12019-12027.
95. Magaña, M. M., Lin, S. S., Dooley, K. A. & Osborne, T. F. (1997). Sterol regulation of acetyl coenzyme A carboxylase promoter requires two interdependent binding sites for sterol regulatory element binding proteins. Journal of Lipid Research 38, 1630-1638.
96. Magaña, M. M. & Osborne, T. F. (1996). Two tandem binding sites for sterol regulatory element binding proteins are required for sterol regulation of fatty-acid synthase promoter. Journal of Biological Chemistry 271, 32689-32694.
97. Maier, T., Leibundgut, M. & Ban, N. (2008). The crystal structure of a mammalian fatty acid synthase. Science 321, 1315-1322.
98. Mainous, A. G., Tanner, R. J., Baker, R., Zayas, C. E. & Harle, C. A. (2014). Prevalence of prediabetes in England from 2003 to 2011: population-based, cross-sectional study. BMJ Open 4: 6 e005002.
99. Majerus, P. W., Alberts, A. W. & Vagelos, P. R. (1964). The acyl carrier protein of fatty acid synthesis: purification, physical properties, and substrate binding site. Proceedings of the National Academy of Sciences of the United States of America 51, 1231-1238.
100. Marceau, P., Biron, S., Hould, F. S., Marceau, S., Simard, S., Thung, S. N. & Kral, J. G. (1999). Liver pathology and the metabolic syndrome X in severe obesity. Journal of Clinical Endocrinology & Metabolism 84, 1513-1517.
101. Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N. & Rizzetto, M. (2003). Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37, 917-923.
102. Masuoka, H. C. & Chalasani, N. (2013). Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Annals of the New York Academy of Sciences 1281, 106-122.
103. Matsumoto, M., Ogawa, W., Akimoto, K., Inoue, H., Miyake, K., Furukawa, K., Hayashi, Y., Iguchi, H., Matsuki, Y., Hiramatsu, R., Shimano, H., Yamada, N., Ohno, S., Kasuga, M. & Noda, T. (2003). PKC? In liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity. Journal of Clinical Investigation 112, 935-944.
104. Mayes, P. A. (1993). Intermediary metabolism of fructose. The American Journal of Clinical Nutrition 58, 754S-765S.
105. McGarry, J. D. (1992). What if Minkowski had been ageusic? An alternative angle on diabetes. Science (New York, N.Y.) 258, 766-770.
106. Medzhitov, R., Preston-Hurlburt, P. & Janeway, C. A. (1997). A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397.
107. Michael, M. D., Kulkarni, R. N., Postic, C., Previs, S. F., Shulman, G. I., Magnuson, M. A. & Kahn, C. R. (2000). Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Molecular Cell 6, 87-97.
108. Mikkelsen, J., Hojrup, P., Rasmussen, M. M., Roepstorff, P. & Knudsen, J. (1985). Amino acid sequence around the active-site serine residue in the acyltransferase domain of goat mammary fatty acid synthetase. Biochemical Journal 227, 21-27.
109. Monetti, M., Levin, M. C., Watt, M. J., Sajan, M. P., Marmor, S., Hubbard, B. K., Stevens, R. D., Bain, J. R., Newgard, C. B., Farese, R. V. Sr., Hevener, A. L. & Farese, R. V. Jr. (2007). Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metabolism 6, 69-78.
110. Moon, Y.-A., Liang, G., Xie, X., Frank-Kamenetsky, M., Fitzgerald, K., Koteliansky, V., Brown, M. S., Goldstein, J. L. & Horton, J. D. (2012). The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metabolism 15, 240-246.
111. Moore, D. D. (2012). A common thread connects antidiabetic effects of multiple nuclear receptors. Cell Metabolism 15, 615-622.
112. Mueckler, M. & Thorens, B. (2013). The SLC2 (GLUT) family of membrane transporters. Molecular Aspects of Medicine 34, 121-138.
113. Munday, M. (2001). Regulation of mammalian acetyl-CoA carboxylase. Biochemical Society Transactions 30, 1059-1064.
114. Murphy, E. J. (2006). Stable isotope methods for the in vivo measurement of lipogenesis and triglyceride metabolism. Journal of Animal Science 84, E94-E104.
115. Murphy, R., Carroll, R. W. & Krebs, J. D. (2013). Pathogenesis of the metabolic syndrome: insights from monogenic disorders. Mediators of Inflammation 2013, 920214.
116. Nagai, Y., Yonemitsu, S., Erion, D. M., Iwasaki, T., Stark, R., Weismann, D., Dong, J., Zhang, D., Jurczak, M. J., Löffler, M. G., Cresswell, J., Yu, X. X., Murray, S. F., Bhanot, S., Monia, B. P., Bogan, J. S., Samuel, V. & Shulman, G. I. (2009). The role of peroxisome proliferator-activated receptor γ coactivator-1 β in the pathogenesis of fructose-induced insulin resistance. Cell Metabolism 9, 252-264.
117. Olofsson, S.-O., Stillemark-Billton, P. & Asp, L. (2000). Intracellular assembly of VLDL: two major steps in separate cell compartments. Trends in Cardiovascular Medicine 10, 338-345.
118. Oosterveer, M. H. & Schoonjans, K. (2014). Hepatic glucose sensing and integrative pathways in the liver. Cellular and Molecular Life Sciences 71, 1453-1467.
119. Ortiz-Lopez, C., Lomonaco, R., Orsak, B., Finch, J., Chang, Z., Kochunov, V. G., Hardies, J. & Cusi, K. (2012). Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 35, 873-878.
120. Park, Y. K. & Yetley, E. A. (1993). Intakes and food sources of fructose in the United States. The American Journal of Clinical Nutrition 58, 737S-747S.
121. Parks, E. J., Skokan, L. E., Timlin, M. T. & Dingfelder, C. S. (2008). Dietary sugars stimulate fatty acid synthesis in adults. The Journal of Nutrition 138, 1039-1046.
122. Paschos, P. & Paletas, K. (2009). Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 13, 9-19.
123. Peterson, T. R., Sengupta, S. S., Harris, T. E., Carmack, A. E., Kang, S. A., Balderas, E., Guertin, D. A., Madden, K. L., Carpenter, A. E., Finck, B. N. & Sabatini, D. M. (2011). mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 146, 408-420.
124. Pettinelli, P., del Pozo, T., Araya, J., Rodrigo, R., Araya, A. V., Smok, G., Csendes, A., Gutierrez, L., Rojas, J., Korn, O., Maluenda, F., Diaz, J. C., Rencoret, G., Braghetto, I., Castillo, J., Poniachik, J. & Videla, L. A. (2009). Enhancement in liver SREBP-1c/PPAR-α ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1792, 1080-1086.
125. Poitout, V. & Robertson, R. P. (2002). Minireview: secondary β-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Endocrinology 143, 339-342.
126. Qin, W., Sundaram, M., Wang, Y., Zhou, H., Zhong, S., Chang, C.-C., Manhas, S., Yao, E. F., Parks, R. J., McFie, P. J., Stone, S. J., Jiang, Z. G., Wang, C., Figeys, D., Jia, W. & Yao, Z. (2011). Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen. Journal of Biological Chemistry 286, 27769-27780.
127. Raabe, M., Véniant, M. M., Sullivan, M. A., Zlot, C. H., Björkegren, J., Nielsen, L. B., Wong, J. S., Hamilton, R. L. & Young, S. G. (1999). Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. Journal of Clinical Investigation 103, 1287-1298.
128. Repa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L. & Mangelsdorf, D. J. (2000). Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXR? and LXR? Genes & Development 14, 2819-2830.
129. Reyna, S. M., Ghosh, S., Tantiwong, P., Meka, C. S. R., Eagan, P., Jenkinson, C. P., Cersosimo, E., DeFronzo, R. A., Coletta, D. K., Sriwijitkamol, A. & Musi, N. (2008). Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes 57, 2595-2602.
130. Ricoult, S. J. H. & Manning, B. D. (2013). The multifaceted role of mTORC1 in the control of lipid metabolism. EMBO Reports 14, 242-251.
131. Ruderman, N. B., Saha, A. K. & Kraegen, E. W. (2003). Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology 144, 5166-5171.
132. Russell, W. R., Hoyles, L., Flint, H. J. & Dumas, M.-E. (2013). Colonic bacterial metabolites and human health. Current Opinion in Microbiology 16, 246-254.
133. Rustaeus, S., Lindberg, K., Stillemark, P., Claesson, C., Asp, L., Larsson, T., Borén, J. & Olofsson, S.-O. (1999). Assembly of very low density lipoprotein: a two-step process of apolipoprotein B core lipidation. The Journal of Nutrition 129, 463S-466S.
134. Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J. & Shulman, G. I. (2004). Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. Journal of Biological Chemistry 279, 32345-32353.
135. Samuel, V. T., Petersen, K. F. & Shulman, G. I. (2010). Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375, 2267-2277.
136. Savage, D. B., Choi, C. S., Samuel, V. T., Liu, Z.-X., Zhang, D., Wang, A., Zhang, X.-M., Cline, G. W., Yu, X. X., Geisler, J. G., Bhanot, S., Monia, B. P. & Shulman, G. I. (2006). Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. Journal of Clinical Investigation 116, 817-824.
137. Schwarz, J. M., Linfoot, P., Dare, D. & Aghajanian, K. (2003). Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. American Journal of Clinical Nutrition 77, 43-50.
138. Schwarz, J. M., Neese, R. A., Turner, S., Dare, D. & Hellerstein, M. K. (1995). Short-term alterations in carbohydrate energy intake in humans. Striking effects on hepatic glucose production, de novo lipogenesis, lipolysis, and whole-body fuel selection. Journal of Clinical Investigation 96, 2735-2743.
139. Semple, R. K., Sleigh, A., Murgatroyd, P. R., Adams, C. A., Bluck, L., Jackson, S., Vottero, A., Kanabar, D., Charlton-Menys, V., Durrington, P., Soos, M. A., Carpenter, T. A., Lomas, D. J., Cochran, E. K., Gorden, P., O'Rahilly, S. & Savage, D. B. (2009). Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. The Journal of Clinical Investigation 119, 315-322.
140. Shi, Y. & Cheng, D. (2008). Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism. American Journal of Physiology: Endocrinology and Metabolism 297, E10-E18.
141. Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H. & Flier, J. S. (2006). TLR4 links innate immunity and fatty acid-induced insulin resistance. Journal of Clinical Investigation 116, 3015-3025.
142. Shimomura, I., Hammer, R. E., Richardson, J. A., Ikemoto, S., Bashmakov, Y., Goldstein, J. L. & Brown, M. S. (1998). Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes & Development 12, 3182-3194.
143. Shimomura, I., Matsuda, M., Hammer, R. E., Bashmakov, Y., Brown, M. S. & Goldstein, J. L. (2000). Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Molecular Cell 6, 77-86.
144. Siddiqi, S. A. (2008). VLDL exits from the endoplasmic reticulum in a specialized vesicle, the VLDL transport vesicle, in rat primary hepatocytes. Biochemical Journal 413, 333-342.
145. Smith, S. (1994). The animal fatty acid synthase: one gene, one polypeptide, seven enzymes. The FASEB Journal 8, 1248-1259.
146. Smith, S. & Tsai, S.-C. (2007). The type I fatty acid and polyketide synthases: a tale of two megasynthases. Natural Product Reports 24, 1041-1072.
147. Sookoian, S. & Pirola, C. J. (2008). Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. Journal of Hepatology 49, 600-607.
148. Sparks, J. D., Sparks, C. E. & Adeli, K. (2012). Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology 32, 2104-2112.
149. Spruss, A., Kanuri, G., Wagnerberger, S., Haub, S., Bischoff, S. C. & Bergheim, I. (2009). Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 50, 1094-1104.
150. Su, G. L. (2002). Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. American Journal of Physiology - Gastrointestinal and Liver Physiology 283, G256-G265.
151. Sun, Z. & Lazar, M. A. (2013). Dissociating fatty liver and diabetes. Trends in Endocrinology and Metabolism: TEM 24, 4-12.
152. Sun, L.-P., Seemann, J., Goldstein, J. L. & Brown, M. S. (2007). Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: insig renders sorting signal in Scap inaccessible to COPII proteins. Proceedings of the National Academy of Sciences of the United States of America 104, 6519-6526.
153. Sundaram, M. & Yao, Z. (2010). Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutrition & Metabolism 7, 1-17.
154. Swift, L. L. (1996). Role of the Golgi apparatus in the phosphorylation of apolipoprotein B. Journal of Biological Chemistry 271, 31491-31495.
155. Taniguchi, C. M., Kondo, T., Sajan, M., Luo, J., Bronson, R., Asano, T., Farese, R., Cantley, L. C. & Kahn, C. R. (2006). Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCλ/ζ. Cell Metabolism 3, 343-353.
156. Tappy, L. & Lê, K.-A. (2010). Metabolic effects of fructose and the worldwide increase in obesity. Physiological Reviews 90, 23-46.
157. Thuy, S., Ladurner, R., Volynets, V., Wagner, S., Strahl, S., Königsrainer, A., Maier, K.-P., Bischoff, S. C. & Bergheim, I. (2008). Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. The Journal of Nutrition 138, 1452-1455.
158. Tiwari, S. & Siddiqi, S. A. (2012). Intracellular trafficking and secretion of VLDL. Arteriosclerosis, Thrombosis, and Vascular Biology 32, 1079-1086.
159. Topping, D. L. & Mayes, P. A. (1972). The immediate effects of insulin and fructose on the metabolism of the perfused liver. Changes in lipoprotein secretion, fatty acid oxidation and esterification, lipogenesis and carbohydrate metabolism. Biochemical Journal 126, 295-311.
160. Tran, K., Thorne-Tjomsland, G., DeLong, C. J., Cui, Z., Shan, J., Burton, L., Jamieson, J. C. & Yao, Z. (2002). Intracellular assembly of very low density lipoproteins containing apolipoprotein B100 in rat hepatoma McA-RH7777 cells. Journal of Biological Chemistry 277, 31187-31200.
161. Uyeda, K. & Repa, J. J. (2006). Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metabolism 4, 107-110.
162. Vanni, E., Bugianesi, E., Kotronen, A., De Minicis, S., Yki-Järvinen, H. & Svegliati-Baroni, G. (2010). From the metabolic syndrome to NAFLD or vice versa? Digestive and Liver Disease 42, 320-330.
163. Vernon, G., Baranova, A. & Younossi, Z. M. (2011). Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology & Therapeutics 34, 274-285.
164. Villanova, N., Moscatiello, S., Ramilli, S., Bugianesi, E., Magalotti, D., Vanni, E., Zoli, M. & Marchesini, G. (2005). Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42, 473-480.
165. Vos, M. B., Kimmons, J. E., Gillespie, C., Welsh, J. & Blanck, H. M. (2008). Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. The Medscape Journal of Medicine 10(7): 160.
166. Wakil, S. J. (1989). Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28, 4523-4530.
167. Wang, H., Gilham, D. & Lehner, R. (2007). Proteomic and lipid characterization of apolipoprotein B-free luminal lipid droplets from mouse liver microsomes implications for very low density lipoprotein assembly. Journal of Biological Chemistry 282, 33218-33226.
168. Wei, Y., Wang, D. & Pagliassotti, M. J. (2005). Fructose selectively modulates c-jun N-terminal kinase activity and insulin signaling in rat primary hepatocytes. The Journal of Nutrition 135, 1642-1646.
169. von Wettstein-Knowles, P., Olsen, J. G., McGuire, K. A. & Henriksen, A. (2006). Fatty acid synthesis. FEBS Journal 273, 695-710.
170. Wiegman, C. H., Bandsma, R. H. J., Ouwens, M., van der Sluijs, F. H., Havinga, R., Boer, T., Reijngoud, D.-J., Romijn, J. A. & Kuipers, F. (2003). Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin. Diabetes 52, 1081-1089.
171. Williams, K. H., Shackel, N. A., Gorrell, M. D., McLennan, S. V. & Twigg, S. M. (2013). Diabetes and nonalcoholic fatty liver disease: a pathogenic duo. Endocrine Reviews 34, 84-129.
172. Wilson, P. W. F., D'Agostino, R. B., Parise, H., Sullivan, L. & Meigs, J. B. (2005). Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112, 3066-3072.
173. Witkowski, A., Joshi, A. K. & Smith, S. (1997). Characterization of the interthiol acyltransferase reaction catalyzed by the β-Ketoacyl synthase domain of the animal fatty acid synthase†. Biochemistry 36, 16338-16344.
174. Yellaturu, C. R., Deng, X., Cagen, L. M., Wilcox, H. G., Mansbach, C. M. II, Siddiqi, S. A., Park, E. A., Raghow, R. & Elam, M. B. (2009). Insulin enhances post-translational processing of nascent SREBP-1c by promoting its phosphorylation and association with COPII vesicles. The Journal of Biological Chemistry 284, 7518-7532.
175. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L. & Friedman, J. M. (1994). Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432.